Literature DB >> 20685955

An update on pharmacological interventions for diabetic foot ulcers.

Christy L Scimeca1, Manish Bharara, Timothy K Fisher, Heather Kimbriel, Joseph L Mills, David G Armstrong.   

Abstract

Diabetic foot ulcers are the most common lower extremity complications of diabetes. Peripheral neuropathy and peripheral vascular disease are the underlying risk factors for diabetic foot ulcers, subsequently leading to infections and requiring antimicrobial therapy for the management of the disease. Each risk factor is a target for clinical intervention, with the intent to delay or prevent disease progression to amputation. The effective therapy includes interdisciplinary care, which involves optimized pharmacological interventions in concert with other treatments such as debridement strategies and specialized wound dressings. The pharmacological therapy alone cannot lead to successful therapy, and therefore, these supplementary techniques/modalities should not be overlooked. It is therefore the aim of this report to review various pharmacological interventions, specific to the diabetic foot and wound healing, along with incorporation of advanced therapies required to achieve a multifaceted treatment of diabetic foot ulcers and provide basis for superior drugs as well as drug delivery systems.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20685955     DOI: 10.1177/1938640010376994

Source DB:  PubMed          Journal:  Foot Ankle Spec        ISSN: 1938-6400


  2 in total

1.  Knockout of Angiotensin AT2 receptors accelerates healing but impairs quality.

Authors:  Mahya Faghih; Sayed M Hosseini; Barbara Smith; Amir Mehdi Ansari; Frank Lay; Ali Karim Ahmed; Tedashi Inagami; Guy P Marti; John W Harmon; Jeremy D Walston; Peter M Abadir
Journal:  Aging (Albany NY)       Date:  2015-12       Impact factor: 5.682

2.  Angiotensin-converting enzyme inhibitor reduces scar formation by inhibiting both canonical and noncanonical TGF-β1 pathways.

Authors:  Qing-Qing Fang; Xiao-Feng Wang; Wan-Yi Zhao; Shi-Li Ding; Bang-Hui Shi; Ying Xia; Hu Yang; Li-Hong Wu; Cai-Yun Li; Wei-Qiang Tan
Journal:  Sci Rep       Date:  2018-02-20       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.